Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Böwe Systec International and Strålfors in joint venture
Mandate

Böwe Systec International and Strålfors in joint venture

May 12, 2005

Roll Systems Inc., the US based manufacturer of paper handling, converting and monitoring systems for digital printers, and the Lasermax division, a business that supplies paper handling equipment for digital printers, have combined in a 50:50 joint venture to form Lasermax Roll Systems AB, in a transaction valued at approximately USD 44m. Roll Systems Inc. is a subsidiary of Böwe Systec International Gmbh, the German supplier of paper management systems for high volume mail processing and the Lasermax is a division of Strålfors, the Sweden based provider of information transfer solutions

Vinge acted for Böwe Systec International GmbG.
Jan Örtenholm (reponsible partner)
Jesper Ottergren, Emma Olnäs, Anna Jonsson, Magnus Larsson, Environmental law, and Maria Strömhage, Employment Law (associates)

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024